Clinical trial
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or…
NCT00268255 · Barbara Ann Karmanos Cancer Institute, Other · Withdrawn
Key facts
| NCT number | NCT00268255 |
|---|---|
| Title | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer |
| Official title | Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | AstraZeneca Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gefitinib, adjuvant therapy, enzyme inhibitor therapy, neoadjuvant therapy, protein tyrosine kinase inhibitor therapy, radiation therapy, radiosensitization |
| Enrollment | 0 |
| First posted | Dec 22, 2005 |
| Last update posted | Apr 16, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: